Vaxcyte (NASDAQ: PCVX)
$32.53
(-0.2%)
-$0.05
Price as of June 30, 2025, 3:58 p.m. ET
Vaxcyte Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vaxcyte Company Info
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.
News & Analysis
Featured Article
SPDR S&P Biotech ETF (XBI): How to Buy
Rachel Warren | Jan 25, 2025
Featured Article
Why Shares of Vaxcyte Rose 110.7% This Week
The company released early data for a promising pneumonia vaccine.
Jim Halley | Oct 29, 2022
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.